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Abstract
Post-stroke dysphagia (a difficulty in swallowing after a stroke) is a common and expensive complication of acute stroke
and is associated with increased mortality, morbidity, and institutionalization due in part to aspiration, pneumonia, and
malnutrition. Although most patients recover swallowing spontaneously, a significant minority still have dysphagia at six
months. Although multiple advances have been made in the hyperacute treatment of stroke and secondary prevention,
the management of dysphagia post-stroke remains a neglected area of research, and its optimal management, including
diagnosis, investigation and treatment, have still to be defined.
Keywords
Stroke, dysphagia, treatment, randomized controlled trial, design, pneumonia, aspiration, rehabilitation
Received: 30 August 2015; accepted: 21 December 2015
Background
Stroke is recognized as a leading cause of death and
disability worldwide and is associated with multiple
medical complications leading to prolonged hospital
admissions and signiﬁcant health care costs.1 Post-
stroke dysphagia (PSD), deﬁned here as diﬃculty in
swallowing after a stroke, is a common complication
aﬀecting many patients in the ﬁrst few hours and days
after ictus. PSD is associated with increased mortality
and morbidity due in part to aspiration, pneumonia,
and malnutrition. Although many stroke patients
recover swallowing spontaneously, 11–50% still have
dysphagia at six months.2,3 Persistent dysphagia inde-
pendently predicts poor outcome and institutionaliza-
tion.4 Dysphagia leading to aspiration of ingested
foods, liquids, or oral secretions, is thought to be the
primary risk factor for pneumonia after stroke.5
Dysphagic patients are three times, and those with con-
ﬁrmed aspiration eleven times, more likely to develop
pneumonia.1,6 A recent large retrospective US study of
stroke patients quantiﬁed the individual cost of pneu-
monia and associated mortality as $21,338. The relative
risk of hospital death in stroke patients with pneumo-
nia is 5.7 (95% CI, 5.4–6.0).5
Although multiple advances have been made in the
hyper acute treatment of stroke (e.g. with thrombolysis,
mechanical thrombectomy, and hemicraniectomy), and
secondary prevention (antithrombotics, blood pressure
lowering, lipid lowering), the management of PSD
remains a neglected area of research. As such, the opti-
mal management of PSD, including diagnosis, investi-
gation and treatment, remains to be deﬁned.
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Epidemiology of PSD
Globally, 15 million people suﬀer a stroke annually7
and up to 65% have swallowing problems of whom
half will be symptomatic.8 Some early studies included
people with diagnosed dysphagia who were referred for
further assessment and this increased artiﬁcially the rate
of aspiration.9,10 The true prevalence of dysphagia can
only be established by studying an unselected stroke
population3,11 and there have been no such recent
studies.
In acute stroke, the prevalence of dysphagia has
been reported as between 28 and 65%,3,11–13 a variation
that reﬂects diﬀerences in the assessment of dysphagia,
setting, and timing of the test used. Dysphagia
improves signiﬁcantly during the early days and after
two weeks 90% of patients swallow safely.3,8 although
a small proportion will have problems for longer.2
Further, some patients who appear to have a safe swal-
low at three months are found to have diﬃculties again
at six.3,11 In general, if the swallow does not show any
signs of recovery in the ﬁrst 10 days after stroke, the
return of a safe swallow may take up two or three
months to show signs of recovery.14
Aspiration in dysphagic patients is often not asso-
ciated with a cough response or outward signs of diﬃ-
culty in swallowing. This absence of any outward sign
or distress is known as silent aspiration and has been
reported as occurring in over 40% of patients.15 Since
there is an association between aspiration and abnor-
mal pharyngeal sensation, with 8% of patients silently
aspirating,16 silent aspiration is considered to be related
to sensory loss or gradual desensitization if aspiration is
chronic.17 Since 100% of dysphagic patients showed
either unilateral or bilateral sensory loss in one study,
and a sensory deﬁcit exists in the pharynx and larynx in
stroke patients with dysphagia, it has been concluded
that the severity of laryngeal sensory deﬁcits determines
a predisposition to aspiration.18
Mechanisms of PSD
PSD is thought to be due to damage to the cortex and
subcortical structures. Cortical re-organization then
leads to swallowing recovery. Studies using transcranial
magnetic stimulation (TMS) have shown that pha-
ryngeal musculature is represented bilaterally, but
asymmetrically, in the cerebral cortex of healthy volun-
teers.19 A stroke lesion aﬀecting the ‘‘dominant swal-
lowing hemisphere’’ may therefore be responsible for
dysphagia following unilateral hemispheric stroke.15
In an attempt to understand the mechanism for recov-
ery of swallowing after stroke, swallowing was studied by
videoﬂuoroscopy (VFS) and TMS mapping over time in
28 hemispheric stroke patients. Subjects who were non-
dysphagic after hemispheric stroke had greater pharyn-
geal cortical representation in the contralesional hemi-
sphere as compared to dysphagic subjects. TMS follow-
up data at one and three months indicated that subjects
who recovered swallowing function had signiﬁcantly
greater pharyngeal representation in the unaﬀected hemi-
sphere as compared to baseline. These ﬁndings suggest
that re-organization in the contralesional hemisphere is
key in swallowing recovery,20 as illustrated in Figure 1.
A recent functional magnetic resonance imaging
study comparing cortical activations during swallowing
between dysphagic hemispheric stroke patients and
healthy subjects conﬁrmed compensatory recruitment
and activation of regions of the cerebral cortex in the
intact hemisphere, supporting the theory that changes
Figure 1. Expansion of pharyngeal motor cortex on unlesioned hemisphere during swallowing recovery after stroke. Magnetic
resonance image with co-registered topographic data from transcranial magnetic stimulation at baseline, one month, and three
months after enrolment.20
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in the unaﬀected hemisphere are crucial in swallow-
ing recovery.21 Moreover, a magnetoencephalography
(MEG) study imaged swallowing activations in sub-
acute stroke patients with and without dysphagia com-
pared with healthy controls described similar evidence
for increased contralesional activity being predictive
of no dysphagia.22 Thus, neuroplasticity is likely
to play a signiﬁcant role in the recovery of swallowing
function.23
In addition to the neuropathophysiological changes
described above, dysphagia will also occur when level
of consciousness is reduced, either acutely due to a
large stroke lesion with associated edema, or later due
to delirium in which case the size and location of stroke
will be less important.
Complications of PSD
Complications of dysphagia include the consequences
of aspiration: pneumonia, recurrent cough, and chok-
ing, and those of modiﬁcations to dietary and ﬂuid
intake: compromised nutrition and hydration, reduced
quality of life, and social isolation.
Pneumonia is a frequent complication of stroke,
occurring in around 10% of hospitalized patients.24
In those at greatest risk because of advanced age,
severe stroke, and PSD, the incidence of pneumonia
may be as high as 40%.25 Conﬁrmed aspiration is
strongly associated with pneumonia (relative risk
11.56; 95% CI 3.36 to 39.77).8 Current thinking recog-
nizes the potential interplay between poor oral health,
aspiration, and immune suppression in determining
susceptibility to pneumonia.26 Pneumonia most often
presents in the ﬁrst week after a stroke, probably
because of the high prevalence of dysphagia and the
extent of immune suppression during the acute phase.
Nevertheless, the diagnosis of pneumonia complicating
stroke remains challenging as its presentation may be
non-speciﬁc and investigations such as chest radiog-
raphy and microbiological specimens are of limited
value.27 This has signiﬁcant implications for clinical
care and research that considers pneumonia as a trial
endpoint and recent consensus diagnostic criteria have
been proposed to address this.28
Patients developing pneumonia are more likely to
die or survive dependent on others,24,29,30 and have a
longer stay in hospital. As compared to alternative set-
tings, care on a stroke unit compared to alternative
settings reduces the frequency of pneumonia (odds
ratio 0.60; 95% CI 0.42 to 0.87).31 Little is known
about the impact of particular care processes such as
positioning, early swallow screening, and oral care
practices. The time trend in pneumonia prevalence in
stroke units is unclear, for example, one registry study
suggested no signiﬁcant change in pneumonia
prevalence between 1998 and 2007.32 Pneumonia
remains an important and modiﬁable complication of
stroke, and strategies to prevent it such as reducing
aspiration could signiﬁcantly improve outcomes.
Compromised nutrition, hydration, and poor quality
of life caused by PSD have attracted less clinical and
research attention than pneumonia. In a systematic
review from 2009, the chance of malnutrition increased
in patients with dysphagia particularly in the post-acute
phase.33 The conclusions were limited by widely vary-
ing deﬁnitions and prevalence of both dysphagia and
malnutrition. The validity and utility of the available
methods for assessing nutritional status in patients with
stroke such as the Demiquet Index, anthropometry,
and those for hydration status, are unclear and need
further evaluation. Dysphagia-related quality of life
tools such as SWAL-QUAL and SWAL-CARE are
available34 but these were not derived in patients with
stroke and require evaluation in this setting.
Diagnosis: Clinical and instrumental
Dysphagia can be diagnosed by clinical bedside assess-
ment (CBA), or instrumentally by VFS, or by ﬁberoptic
endoscopic evaluation of swallowing (FEES). CBA
consists of a detailed oral examination and an assess-
ment with food and liquid to ascertain oral and pha-
ryngeal competency. Several methodological variations
have been reported.35 CBA predicts pharyngeal dys-
phagia poorly and has been criticized for its inaccuracy
in identifying aspiration,36,37 missing up to 40% of
people who aspirate.36
In hyperacute stroke studies, swallowing has been
assessed using a water swallow test, a screening test
rather than full assessment.38 Many subsequent swal-
low screens have been based on this with or without a
scoring mechanism.39–42 Some tests require specialist
training or are copyrighted (e.g. TOR-BSST).39
Assessment later after the stroke is more comprehensive
but will detect fewer cases as swallowing improves or
recovers.11,43 It is diﬃcult to estimate how many
patients simply have diﬃculty swallowing and how
many are also aspirating as few studies have performed
routine VFS in the ﬁrst few days.
It is important to decide which aspect of swallowing,
for example, clinical dysphagia or radiological aspir-
ation, is the focus of study. This will determine the
type of assessment required and the relevance to clinical
practice. For example, it remains unclear whether a
ﬁnding of asymptomatic aspiration on FEES is relevant
or whether a minor tongue movement abnormality on
clinical examination is important if it does not cause
symptoms.
VFS is an instrumental assessment of swallowing
and involves swallowing a radiological contrast agent
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such as barium. It is expensive as it needs a radiology
suite and often a number of diﬀerent staﬀ. Many
patients are too ill to travel to radiology and sit up
for long enough to be assessed. It involves radiation
exposure (although this is of less relevance to stroke
patients) and is not readily repeatable. Hence, it is
impractical to perform VFS in every case.
In FEES a laryngoscope is passed transnasally to the
hypopharynx to view the larynx and pharynx. Food and
drinks are dyed to aid visualization of the bolus. FEES
allows an assessment of the anatomy, secretions and of
food and drink management. Information is obtained
on the ability to protect the airway, timing of the bolus
through the hypopharynx and ability to clear the bolus
during the swallow. It also allows the clinician to see
pooling and residue in the hypopharynx and detect
aspiration.44,45 The equipment is portable, sitting is
not essential, and the procedure can be performed at
the bedside. It is a repeatable, and safe allowing more
swallows to be tested. Patients can be assessed while
eating a full meal rather than with the limited number
of spoonful’s of contrast given during VFS. However,
FEES is not routinely available inmany hospitals world-
wide which, like VFS, limits the number of centers which
could participate in research using it as an assessment.
VFS and FEES are considered interchangeable in
clinical practice, especially when examining aspiration
or penetration,45–50 and they are the only two assess-
ments that can diagnose aspiration reliably.51 VFS has
been considered the gold standard for the diagnosis of
dysphagia, but FEES is increasingly seen as a cost-
eﬀective, portable, and reliable alternative.51
Validation of FEES against VFS showed high sensitiv-
ity and speciﬁcity.45,52,53 In one study FEES was shown
to detect aspiration more reliably than VFS.50 Other
assessments, such as cervical auscultation or pulse
oximetry are other potential approaches.
In conclusion, instrumental assessment is considered
the gold standard in the diagnosis of dysphagia, but
requires specialist staﬀ and equipment and therefore
cannot readily be conducted within a few hours of
stroke onset, as would be needed in a study of early
intervention. CBA is the only option in this situation
but is not as reliable.
Dysphagia management
The primary aim of dysphagia management has been to
reduce aspiration and to manage swallowing diﬃculties
rather than rehabilitate the swallow. This is partly due
to the heterogeneity of swallowing diﬃculties and
developing knowledge of the normal and disordered
swallow. Management includes modifying food and
ﬂuid, altering posture and changing swallowing strate-
gies with some rehabilitative techniques. These may be
used independently but are mostly used together.
Management depends on whether the focus is on risk
of aspiration or level of swallow breakdown and can be
individualized.
Compensatory techniques support management of
food and drink within a person’s current situation
and reduce aspiration risk. They are short-term adjust-
ments and may not improve the physiology of the swal-
low or promote neural network swallow recovery.
Postural techniques (e.g. chin tuck) redirect the bolus
and change pharyngeal dimensions. Compensatory
swallow techniques such as the eﬀortful swallow aim
to increase the eﬃcacy and safety of swallowing.
There is some evidence of a reduction in aspiration
with these techniques.54,55
Thickening liquids slow the bolus and increase bolus
cohesion leading to a reduction in penetration and aspir-
ation.56 The quality and extent of modiﬁcation of food
and ﬂuids are inconsistent and subjective as thickness of
ﬂuids depends on the base ﬂuid, temperature, the indi-
vidual making the drink, and the type of thickener,
resulting in variability within and between patients.57
Rehabilitation techniques such as oral and lingual
exercises tend to focus on strength and endurance.58
They result in an increase in isometric pressure, but
are aimed at speciﬁc parts of the swallow so it is not
clear how they generalize to the dynamic swallow.
Other approaches report a more explicit focus on
motor learning principles and the functional swallow-
ing process. One of these with some evidence of eﬀect-
iveness is the McNeill Dysphagia Therapy program.59
More recently, neurostimulation techniques for
rehabilitation have been employed, such as TMS, pha-
ryngeal electrical stimulation (PES), and neuromuscu-
lar electrical stimulation; there is some evidence that
these may reduce aspiration, pharyngeal residue,
length of stay in hospital, and improved swallowing
performance.60 Recent reviews of dysphagia manage-
ment report limited consistency of evidence for inter-
ventions, but with some evidence of eﬀectiveness for
behavioral interventions and PES on aspects of swallow
and functional outcomes.55,61
Although there is little evidence for postural and
compensatory techniques, these are widely but variably
used leading to diﬃculties in establishing what ‘‘usual
care’’ is in a research context. This could be addressed
by cluster rather than patient level randomization.
Issues around subjectivity of ﬂuid modiﬁcation can be
addressed by using pre-thickened bolus which has been
shown to be more consistent.58
Medical treatment of dysphagia
There is no established medical treatment for PSD,
although multiple studies have investigated a variety
International Journal of Stroke, 11(4)
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of interventions, including therapist-delivered, behav-
ioral, acupuncture, electrical or magnetic stimulation,
and drugs. Completed randomized controlled trials are
summarized in a Cochrane Collaboration review61 that
is currently being updated.62 Table 1 summarizes the
main eﬀects of a variety of treatments used in these
trials on a number of diﬀerent outcomes. Overall,
there were few studies when considered by type of treat-
ment, most were single-center, and all were small.
Interpretation of them is further confounded as many
involved mixed populations of patients with diﬀerent
types of dysphagia, not just PSD, and many trials
recruited patients over a wide time range after stroke.
Overall, the quality of most trials judged using
Cochrane Collaboration criteria was low to moderate
although a few were high quality. The existing evidence
demonstrates the necessity for large high quality dys-
phagia-treatment trials.
Prevention of post-stroke pneumonia
Post-stroke pneumonia is due to a combination of dys-
phagia, aspiration,8 and stroke-induced immunosup-
pression.63 It can be caused by bacteria aspirated
form the oropharynx or by the chemical eﬀects of the
gastric acid on the bronchial mucosa.64 Prevention of
pneumonia therefore includes early identiﬁcation of
dysphagia, interventions to reduce the volume and fre-
quency of aspiration and the pathogenicity of the aspir-
ate, enhancement of laryngeal sensation and protective
mechanisms such as cough, and promotion of cortical
plasticity to enhance recovery of the swallow.
Stroke unit care is associated with signiﬁcant reduc-
tions in the incidence of pneumonia.31 This is likely to
be due to timely screening for dysphagia, modiﬁcation
of the consistency of diet and ﬂuids and/or provision
of enteral feeding65,66, and early mobilization.67,68
Pharmacologic approaches could further decrease the
risk of pneumonia. Selective oral decontamination
lowers oropharyngeal colonization with pathogenic
Gram negative bacteria and was associated with a sig-
niﬁcant reduction in pneumonia in a study of 203
patients with acute stroke.69 Prevention of vomiting
and regurgitation is another promising approach, as
stroke does not only cause dysphagia, but is also asso-
ciated with lower esophageal sphincter dysfunction,
gastro-paresis, increased gastric residual volume and
gastro-esophageal reﬂux.70 A recent randomized con-
trolled study of the antiemetic agent metoclopramide
in 60 patients with acute stroke fed via nasogastric
tubes showed a 69% reduction in pneumonia with regu-
lar treatment.71
Pneumonia after stroke could potentially be pre-
vented by the use of prophylactic antibiotics. A
Cochrane review of ﬁve studies including 506 patients
demonstrated that prophylactic antibiotics signiﬁcantly
reduced post-stroke infection but had no eﬀect on mor-
tality.72 Most of the included trials used broad-spectrum
antibiotics, started within 24h of stroke onset and con-
tinued for three to ﬁve days.73,74 While antibiotic
prophylaxis prevented infections overall, there was no
reduction in pneumonia. This was recently conﬁrmed
by two large randomized controlled trials. The
Preventive Antibiotics in Stroke Study (PASS) rando-
mized 2250 unselected patients with acute stroke patients
to prophylactic ceftriaxone and reported an overall
reduction in infections but no eﬀect on pneumonia.75
Similarly, the Stroke-Inf study, a cluster-randomized
study including 1217 patients with acute ischemic
stroke found no eﬀect on pneumonia of prophylaxis
based on co-amoxiclav and clarithromycin although
urinary tract infection was reduced.76 While antibiotic
prophylaxis is clearly eﬀective in the prevention of
extra-pulmonary infections, there is now strong evidence
Table 1. Potential treatments for post-stroke dysphagia and their effects on important outcomes
Intervention Trials Patients Dysphagia Case fatality Pneumonia
Acupuncture 5 321 0.24 (0.13–0.45)
Behavioural 5 423 0.52 (0.30–0.88) 0.83 (0.46–1.51) 0.50 (0.24–1.04)
Drug therapy 2 75 0.48 (0.07–3.35) 1.14 (0.06–21.87) 0.08 (0.02–0.24)
Pharyngeal electrical stimulation 3 66 0.55 (0.15–2.11) 3.75 (0.39–36.18) 0.43 (0.06–3.09)
Neuromuscular electrical stimulation 1 22 0.51 (0.18–1.49) – –
Transcranial direct current stimulation 1 14 0.29 (0.01–8.39) – –
Transcranial magnetic stimulation 4 78 – 0.28 (0.03–2.93) –
Note: Summary results from Cochrane Collaboration review,61 currently being updated.62 Data are odds ratio (95% confidence intervals); odds ratio
less than 1.00 are compatible with benefit – significant results highlighted in bold.
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Table 2. Design considerations for future randomised controlled trials in the management of post-stroke dysphagia
Criteria Approaches Comments
Subjects
Participants  Mixed or pure population of stroke  Focus on stroke
Timing after stroke  Acute phase
 Subacute phase
 Chronic phase
 Depends on study aim
Identification  Dysphagia versus aspiration
 Clinical bedside assessment,
but many different tests and
poor sensitivity and specificity
 Instrumental procedures: VFS and FEES
 Screening versus diagnostic tests
 Ideally, training needs should be minimal
 Large trials will need to avoid
instrumental tests
Intervention
Active  As already studied (Table 1)
 Novel approach
Comparator  Placebo – against active drug
 Sham – against active device92
 No comparator
 Large trials may need a control group
comprising only standard care
Background evidence  Based on systematic review(s),
ideally using individual patent data
 See Table 1
Outcomes
Explanatory or mechanistic
phase II trials
 Resolution of aspiration, e.g. using
FEES or VFS
 Resolution of clinical dysphagia
 Chest infection or pneumonia
 FEES/VFS have limited availability
 Measure at end of treatment or 1–2 weeks
 Outcomes need to be assessed
blinded to assigned intervention
 A validated definition is needed for pneumonia
 Pneumonia may be masked in stroke
Efficacy phase III trials  Resolution of clinical dysphagia
 Avoid chest infection, pneumonia
 Avoid vomiting, aspiration
 Enhance cough reflex
 Avoid, or early removal, of PEG/RIG tube
 Improve functional outcome, e.g. mRS93
 Reduce case fatality
Measure at end of trial, e.g. day 90
 Outcomes need to be assessed blinded
to assigned intervention
Impact  Health economics, based on:
 EuroQoL-5D94
 Cost of mRS outcomes
 Reduce length of stay in hospital
Methodology
Design  Parallel group (most trials), or factorial61
 Activeþ standard care vs Standard care
 Active vs Standard care
 Assess medical and therapist-delivered
interventions in factorial design
Randomisation  Simple
 Stratified/minimised95
 Treatment must be assigned randomly
to allow concealment of allocation
Sample size  10s of patients, single or few sites, for phase II
 100–1000s of patients,
10–100s of sites, for phase III
 What effect size is reasonable to expect?
Training  For clinical bedside assessments, VFS and FEES
(continued)
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form trials using a range of diﬀerent antibiotics that such
prophylaxis does not prevent pneumonia.
Cough is a well-known side eﬀect of angiotensin
converting enzyme inhibitors (ACEIs) and could poten-
tially reduce pneumonia. This has only been tested in
patients with chronic stroke, and eﬀects appeared to be
more pronounced in Asian than Caucasians,77 a popu-
lation that are more sensitive to ACE-I induced cough.
Cilostazol, an antiplatelet agent with vasodilator eﬀects
has also been shown to reduce pneumonia in the
chronic phase of stroke; the mechanism for this is
unknown, but might involve bradykinin and substance
P, as for ACEIs.78 Excessive tracheobronchial sections
(bronchorrhoea) have been described in posterior cir-
culation strokes, and anticholinergic agents could
reduce secretions and pneumonia in this group.79
Pneumonia is an early complication of stroke, and
usually associated with aspiration soon after the acute
event.80 The risk of aspiration declines within the ﬁrst
two weeks after stroke.16 Therefore, prevention should
be started early and continue over the ﬁrst two weeks,
the period when patients are most at risk of aspiration
and pneumonia. As there is no agreed deﬁnition of post-
stroke pneumonia,28 comparison of the eﬀectiveness of
interventions aimed at prevention of pneumonia is diﬃ-
cult. Future studies should use agreed deﬁnitions.27
Oral care
Poor oral care and dental hygiene increase risk of pneu-
monia, cause discomfort, and reduce quality of life after
stroke. There are guidelines for best practice.81 The
majority of data, on which the recommendations are
based, are from ventilated patients on intensive care
units.82,83 Nursing home residents, people with dementia,
or with learning diﬃculties are high-risk groups for poor
mouth care. Poor dental hygiene is recognized as being
associated with vascular disease and is more common in
older people. It is likely that poor oral care is a cause for
pneumonia in this group, particularly if there is also dys-
phagia and in individuals who are enterally fed (Beavan,
Meagher & Robertson, unpublished).
Patients with neurodisability have diﬃculty under-
taking their own oral and dental care due to physical,
perceptual, and cognitive diﬃculties and therefore rely
on help. They may be reluctant to ask for help, as oral
care is not seen as a priority.84 Lack of help is asso-
ciated with poor oral and dental care.
The best way to deliver oral care is uncertain and
practice varies widely.81 Nurses worry about causing
aspiration and therefore, although recommended, few
use toothbrushes or toothpaste. Electric and suction
toothbrushes are a potential option, but they are expen-
sive and it is uncertain if they are of beneﬁt after acute
stroke.85 The ﬂora of the oral cavity is altered by the
stroke itself,69 by concurrent use of antibiotics, the devel-
opment of candida infections, and by the build-up of
oropharyngeal residues and dental plaque. The solutions
used for oral care vary between units. The best agent to
use in stroke patients is unclear but using some form of
diluted chlorhexidine as part of an oral care regime, as in
intensive care, may be beneﬁcial.82 The eﬀectiveness and
risks of pineapple juice (which contains sugar), artiﬁcial
saliva and glycerin sticks are unclear. Glycerin sticks are
discouraged as they may dry the mouth. The production
and consistency of saliva may change post stroke and
drying of the oral cavity may be aﬀected by poor oral
closure and positioning.
Patient and carer perspectives
When admitted to hospital following an acute stroke,
patients and their relatives are often unaware that
stroke can cause swallowing problems. They are fre-
quently surprised, and distressed, when a ‘‘nil by
mouth’’ order is placed until the swallow has been
checked although this practice is evidence-based and
supported by stroke guidelines.86 This surprise is per-
haps understandable as dysphagia is not a symptom a
lay person would associate with stroke and does not
feature in the act FAST campaign, even though drib-
bling saliva is common.
A swallow screen should be performed as early as
possible in the person’s assessment. If the swallow is
considered unsafe, and the person is put ‘‘nil by
mouth,’’ the patients’ and carers’ distress are frequently
exacerbated. Further problems can ensue if no one who
can do a more detailed assessment is available to say
whether the patient must remain nil by mouth, or if
they could manage a modiﬁed diet or ﬂuids safely.
Table 2. Continued
Criteria Approaches Comments
Funding  Academic
 Commercial
 Mixed academic-commercial92
 Placebo or sham-controlled
studies are expensive
DSRS: Dysphagia severity rating scale; EQ-5D: Euro-Qol 5 dimensions (from which health utility status can be calculated); FEES: fiberoptic endoscopic
evaluation of swallowing; mRS: modified Rankin Scale; PEG: Percutaneous Endoscopic Gastrostomy; RIG: Radiologically Inserted Gastrostomy; VFS:
videofluoroscopy.
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Even a modiﬁed diet may cause further distress as it can
be aspirated, causing coughing, or if the patient is unable
to swallow it, collect in a cheek causing ‘‘pouching.’’87
Attention to oral care is particularly important in these
patients for safety and because retained food debris can
cause halitosis, causing further indignity and carer
distress.
All staﬀ working with stroke patients should have
the knowledge and skills appropriate to their role in the
pathway88 including those for the detection and man-
agement of dysphagia and its complications. Inter-
professional competences have been developed to
inform the training and organization of teams in all
aspects of dysphagia.89 Implementation has the poten-
tial to reduce waiting times for swallowing assessments,
improve patient’s safety at mealtimes, and optimizing
dysphagia management, improving both patients and
carers experience.
Training of carers in addition to training of staﬀ is
recommended because diﬃculties with swallowing may
arise not only in hospital but also after discharge, and
those in close contact with the patient have the unique
opportunity to notice the signs: delayed cough after
seemingly drinking competently. Patients are frequently
distressed by the constant stream of saliva. Even if they
are able to eat, patients may not eat in the presence of
others because of failing to meeting other people’s
expectations of well-mannered behavior. This not
only aﬀects the patient but also their carers and
friends.90 Swallowing problems may persist long-term,
and low mood and clinical depression may result.91
Trial design considerations
The design and results of completed trials help when
designing future studies. Key trial designs cover both
generic and dysphagia-speciﬁc factors (Table 2). Trials
must be designed to minimize the potential for bias and
therefore use true randomization that conceals alloca-
tion from the investigator, and outcomes must be
assessed blinded to treatment. Some potential treat-
ments for dysphagia may allow a double-blind design
by using matching placebo for drug therapy or sham
intervention for device studies.92 Where possible, trials
should allow masking of the treating healthcare profes-
sional as well as the patient. However, large trials may
need to have no placebo or sham if they are to replicate
real-world use of the intervention. Either way, trials
involving acupuncture, physical stimulation, or behav-
ioral therapies will need a treating speech and language
therapist or other professional and therefore will inher-
ently have to be open label, albeit with blinded outcome
assessment.
Dysphagia-speciﬁc trial design considerations cover
the type of intervention and outcomes. The primary
outcome will depend on whether the trial is assessing
primarily mechanisms (phase II) or eﬃcacy (phase III
or IV). Mechanistic studies need to focus on tolerability
of the intervention and whether prognostic measures of
aspiration (with assessment using FEES or VFS96) and
dysphagia (using a clinical scale such as the DSRS60)
are reduced. In contrast, phase III trials will need to
assess real-world outcomes that may be dysphagia-
related (such as pneumonia or need for PEG feeding)
or functional (such as the modiﬁed Rankin Scale). Once
the primary outcome is decided, an optimal method of
analysis should be used to minimize sample size for a
given power (with power typically set at 0.90); eﬃcient
statistical analyses can reduce sample size in stroke
trials by 20–30%.97
One caveat when considering the choice of primary
outcome and its analysis is that treatment eﬀects may
move in opposite directions. For example, the large
FOOD-2 trial of timing of tube feeding post stroke
observed a non-signiﬁcant reduction in death and
non-signiﬁcant increase in poor functional outcome
(modiﬁed Rankin Scale 4 or 5).98 (A similar divergence
was seen in the CLOTS-3 trial of intermittent pneu-
matic compression stockings with less death but more
severe dependency.99,100) The underlying issue is that
eﬀective treatment of stroke complications, such as dys-
phagia (or pulmonary embolism as in CLOTS-3), may
reduce death but thereby create a surviving population
of patients with severe stroke who have signiﬁcant
impairment and disability.
A number of trials or observational studies are
ongoing, as summarised in Geeganage et al.61 and
Table 3, the latter focusing on ongoing studies.
Summary
The optimal diagnosis and treatment of PSD remain
unclear and reported trials do not deﬁne optimal man-
agement. Ongoing studies may identify new strategies
although their number is few. Nevertheless, their
results, whether positive, neutral or negative, will help
identify strategies that need testing or rejecting; if any
trial is positive then a further one will probably be
needed to validate the ﬁndings.
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